J Korean Med Sci.  2023 Aug;38(34):e264. 10.3346/jkms.2023.38.e264.

Cost-Effectiveness of Active Surveillance Compared to Early Surgery of Small Papillary Thyroid Cancer: A Retrospective Study on a Korean Population

• Baek HS
• Ha J
• Kim K
• Bae J
• Kim JS
• Kim S
• Lim DJ
• Kim C

• KMID: 2545542
• DOI: http://doi.org/10.3346/jkms.2023.38.e264

Abstract

Background
Recently, active surveillance (AS) has been introduced as an alternative to early surgery (ES) for the management of papillary thyroid microcarcinoma (PTMC), because of its indolent features and low mortality. However, its cost effects have not been determined and the findings of current studies differ, according to each country’s medical system.
Methods
A Markov model was constructed to compare the cost-effectiveness of AS and ES, based on a reference case of a 40-year-old patient diagnosed with PTMC. Costs and transition probabilities were derived from previous clinical studies in Korean populations, and the incremental cost-effectiveness ratio (ICER) and net monetary benefit (NMB) were calculated. The willingness-to-pay (WTP) threshold was set at USD 100,000 per quality-adjusted life year (QALY) gained. Sensitivity analyses were conducted to address the uncertainties in the model’s variables.
Results
From the base scenario, the cumulative costs and effectiveness were both higher in ES than AS. The ICER for ES, compared with AS, was USD 6,619.86/QALY, lower than the set WTP. The NMB difference between AS and ES increased across the stages (USD 5,980 at the first stage and USD 159,667 at the last stage). The ICER increased along with decreasing age and increasing cost of surgery. The higher the ES utility score and the lower that of AS, the more cost-effective ES, with WTP set at USD 30,000.
Conclusion
In the current Korean medical system, ES is more cost-effective than AS. ES is more cost-effective as it is diagnosed at young age and followed-up for a long time.

Keyword

Cost-Effectiveness Analysis; Papillary Thyroid Microcarcinoma; Quality of Life; Active Surveillance; Endocrine Surgical Procedures

Figure

• 

  Fig. 1 The ICER and the NMB according to each stage. (A) The ICER decreased according to the stages. (B) The blue bar represents the NMB of AS and the orange bar represents the NMB of ES. The difference in NMB is increasing with each stage, and is represented as a gray curve.ICER = incremental cost effectiveness ratio, NMB = net monetary benefit, QALY = quality-adjusted life year, AS = active surveillance, ES = early surgery.

• 

  Fig. 2 The results of the one-way sensitivity analysis. (A) The ICER according to age at diagnosis; the ICER decreases with age. (B) The ICER according to surgery costs; the higher surgery costs, the higher the ICER. (C) The ICER according to cost of ultrasonography; the higher the ultrasonography cost, the higher the ICER. (D) The NMB according to mortality after lobectomy. At base case (0.0039), the NMB of ES is higher than NMB of AS. At 0.0139, however, the two lines cross. If the mortality is higher than 0.0139, the NMB of AS is higher than the NMB of ES.ICER = incremental cost effectiveness ratio, NMB = net monetary benefit, ES = early surgery, AS = active surveillance, QALY = quality adjusted life year.

• 

  Fig. 3 The cost-effectiveness acceptability curve and the results of the two-way sensitivity analysis. (A) With the cost-effectiveness acceptability curve, the iterations were reversed when WTP is about USD 5,000. (B) The higher the utility score of ES (≥ about 0.865) and the lower the utility of AS (< about 0.934), the higher the cost-effectiveness of ES, with WTP set at USD 30,000. (C) With lower WTP (USD 5,000), AS was slightly more cost-effective, but the ES was still the most cost-effective.WTP = willingness-to-pay, ES = early surgery, AS = active surveillance.

Reference

1. Hong S, Won YJ, Park YR, Jung KW, Kong HJ, Lee ES, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2017. Cancer Res Treat. 2020; 52(2):335–350. PMID: 32178489.

2. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014; 140(4):317–322. PMID: 24557566.

3. Choi YM, Lee J, Kwak MK, Jeon MJ, Kim TY, Hong EG, et al. Recent changes in the incidence of thyroid cancer in Korea between 2005 and 2018: analysis of Korean national data. Endocrinol Metab (Seoul). 2022; 37(5):791–799. PMID: 36220137.

4. Jeon EJ, Jeong YJ, Park SH, Cho CH, Shon HS, Jung ED. Ultrasonographic characteristics of the follicular variant papillary thyroid cancer according to the tumor size. J Korean Med Sci. 2016; 31(3):397–402. PMID: 26955240.

5. Uppal N, Cunningham Nee Lubitz C, James B. The cost and financial burden of thyroid cancer on patients in the US: a review and directions for future research. JAMA Otolaryngol Head Neck Surg. 2022; 148(6):568–575. PMID: 35511135.

6. Ito Y, Miyauchi A, Kihara M, Higashiyama T, Kobayashi K, Miya A. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid. 2014; 24(1):27–34. PMID: 24001104.

7. Ahn HS, Kim HJ, Welch HG. Korea’s thyroid-cancer “epidemic”--screening and overdiagnosis. N Engl J Med. 2014; 371(19):1765–1767. PMID: 25372084.

8. Jung CK, Bae JS, Park YJ. Re-increasing trends in thyroid cancer incidence after a short period of decrease in Korea: reigniting the debate on ultrasound screening. Endocrinol Metab (Seoul). 2022; 37(5):816–818. PMID: 36220136.

9. Baek HS, Jeong CH, Ha J, Bae JS, Kim JS, Lim DJ, et al. Cost-effectiveness analysis of active surveillance compared to early surgery in small papillary thyroid cancer: a systemic review. Cancer Manag Res. 2021; 13:6721–6730. PMID: 34471385.

10. Boltz MM, Hollenbeak CS, Schaefer E, Goldenberg D, Saunders BD. Attributable costs of differentiated thyroid cancer in the elderly Medicare population. Surgery. 2013; 154(6):1363–1369. PMID: 23973115.

11. Kim K, Choi JY, Kim SJ, Lee EK, Lee YK, Ryu JS, et al. Active surveillance versus immediate surgery for low-risk papillary thyroid microcarcinoma patients in South Korea: a cost-minimization analysis from the MAeSTro study. Thyroid. 2022; 32(6):648–656. PMID: 35570657.

12. Gupta N, Verma R, Dhiman RK, Rajsekhar K, Prinja S. Cost-effectiveness analysis and decision modelling: a tutorial for clinicians. J Clin Exp Hepatol. 2020; 10(2):177–184. PMID: 32189934.

13. Kuntz K, Sainfort F, Butler M, Taylor B, Kulasingam S, Gregory S, et al. Decision and Simulation Modeling in Systematic Reviews. Methods Research Report. (Prepared by the University of Minnesota Evidence-based Practice Center under Contract No. 290-2007-10064-I.) AHRQ Publication No. 11(13)-EHC037-EF. Rockville, MD, USA: Agency for Healthcare Research and Quality;2013.

14. Korea National Cancer Center. Cancer statistics according to age. Accessed January 30, 2023. https://www.cancer.go.kr/ .

15. Zhang HS, Lee EK, Jung YS, Nam BH, Jung KW, Kong HJ, et al. Total thyroidectomy’s association with survival in papillary thyroid cancers and the high proportion of total thyroidectomy in low-risk patients: analysis of Korean nationwide data. Surgery. 2019; 165(3):629–636. PMID: 30342774.

16. Korea National Statistics Office. Life table. Updated 2022. Accessed January 30, 2023. https://kosis.kr/statHtml/statHtml.do?orgId=101&tblId=DT_1B42&conn_path=I2 .

17. Health Insurance Review & Assessment Service. 2021 Economic evaluation guidelines in medicine and drugs. Updated 2021. Accessed January 30, 2023. https://www.hira.or.kr/ebooksc/ebook_630/ebook_630_202103150917443810.pdf .

18. Bertram MY, Lauer JA, De Joncheere K, Edejer T, Hutubessy R, Kieny MP, et al. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016; 94(12):925–930. PMID: 27994285.

19. Health Insurance Review & Assessment Service. Medical fee schedule of health service in Korea under national health insurance coverage. Updated 2021. Accessed January 30, 2023. https://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA020002000100&brdScnBltNo=4&brdBltNo=9105 .

20. Kwon H, Jeon MJ, Kim WG, Park S, Kim M, Song DE, et al. A comparison of lobectomy and total thyroidectomy in patients with papillary thyroid microcarcinoma: a retrospective individual risk factor-matched cohort study. Eur J Endocrinol. 2017; 176(4):371–378. PMID: 28089996.

21. Jeon YW, Gwak HG, Lim ST, Schneider J, Suh YJ. Long-term prognosis of unilateral and multifocal papillary thyroid microcarcinoma after unilateral lobectomy versus total thyroidectomy. Ann Surg Oncol. 2019; 26(9):2952–2958. PMID: 31264119.

22. Kim SK, Park I, Woo JW, Lee JH, Choe JH, Kim JH, et al. Total thyroidectomy versus lobectomy in conventional papillary thyroid microcarcinoma: analysis of 8,676 patients at a single institution. Surgery. 2017; 161(2):485–492. PMID: 27593085.

23. Oh HS, Ha J, Kim HI, Kim TH, Kim WG, Lim DJ, et al. Active surveillance of low-risk papillary thyroid microcarcinoma: a multi-center cohort study in Korea. Thyroid. 2018; 28(12):1587–1594. PMID: 30226447.

24. Houten R, Fleeman N, Kotas E, Boland A, Lambe T, Duarte R. A systematic review of health state utility values for thyroid cancer. Qual Life Res. 2021; 30(3):675–702. PMID: 33098494.

25. Jones E, Epstein D, García-Mochón L. A procedure for deriving formulas to convert transition rates to probabilities for multistate Markov models. Med Decis Making. 2017; 37(7):779–789. PMID: 28379779.

26. Pyo J, Ock M, Park B, Kim NE, Choi EJ, Park H, et al. Meaning and status of health-related quality of life recognized by medical professionals: a qualitative study. J Korean Med Sci. 2021; 36(3):e20. PMID: 33463094.

27. Lang BH, Wong CK. A cost-effectiveness comparison between early surgery and non-surgical approach for incidental papillary thyroid microcarcinoma. Eur J Endocrinol. 2015; 173(3):367–375. PMID: 26104754.

28. Venkatesh S, Pasternak JD, Beninato T, Drake FT, Kluijfhout WP, Liu C, et al. Cost-effectiveness of active surveillance versus hemithyroidectomy for micropapillary thyroid cancer. Surgery. 2017; 161(1):116–126. PMID: 27839930.

29. White C, Weinstein MC, Fingeret AL, Randolph GW, Miyauchi A, Ito Y, et al. Is less more? A microsimulation model comparing cost-effectiveness of the revised American Thyroid Association’s 2015 to 2009 guidelines for the management of patients with thyroid nodules and differentiated thyroid cancer. Ann Surg. 2020; 271(4):765–773. PMID: 30339630.

30. Oda H, Miyauchi A, Ito Y, Sasai H, Masuoka H, Yabuta T, et al. Comparison of the costs of active surveillance and immediate surgery in the management of low-risk papillary microcarcinoma of the thyroid. Endocr J. 2017; 64(1):59–64. PMID: 27667647.

31. Lin JF, Jonker PK, Cunich M, Sidhu SB, Delbridge LW, Glover AR, et al. Surgery alone for papillary thyroid microcarcinoma is less costly and more effective than long term active surveillance. Surgery. 2020; 167(1):110–116. PMID: 31543327.

32. Youssef MR, Attia AS, Omar M, Aboueisha M, Freeman MN, Shama M, et al. Thyroid lobectomy as a cost-effective approach in low-risk papillary thyroid cancer versus active surveillance. Surgery. 2022; 171(1):190–196. PMID: 34384606.

33. Ernst R. Indirect costs and cost-effectiveness analysis. Value Health. 2006; 9(4):253–261. PMID: 16903995.

34. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014; 371(9):796–797. PMID: 25162885.

35. Jeon MJ, Lee YM, Sung TY, Han M, Shin YW, Kim WG, et al. Quality of life in patients with papillary thyroid microcarcinoma managed by active surveillance or lobectomy: a cross-sectional study. Thyroid. 2019; 29(7):956–962. PMID: 31038017.

36. Nickel B, Tan T, Cvejic E, Baade P, McLeod DS, Pandeya N, et al. Health-related quality of life after diagnosis and treatment of differentiated thyroid cancer and association with type of surgical treatment. JAMA Otolaryngol Head Neck Surg. 2019; 145(3):231–238. PMID: 30653212.

37. Jeon MJ, Kang YE, Moon JH, Lim DJ, Lee CY, Lee YS, et al. Protocol for a Korean Multicenter Prospective Cohort Study of Active Surveillance or Surgery (KoMPASS) in papillary thyroid microcarcinoma. Endocrinol Metab (Seoul). 2021; 36(2):359–364. PMID: 33752303.